Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study
Authors:
- 25 June 2020
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 86 (1) , 129-139
Abstract
Purpose Severe adverse events frequently occur in patients treated with sorafenib, whereas some patients have suboptimal response to sorafenib. We aimed to evaluate the association of sorafenib-induced toxicities and clinical outcomes with the pharmacokinetics of sorafenib in patients with hepatocellular carcinoma (HCC). Methods This was a retrospective, observational study in which 26 HCC patients who had been treated with sorafenib were enrolled between September 2010 and March 2015. The association between trough sorafenib concentration and occurrence of grade ≥ 3 toxicities was evaluated. In addition, we estimated the association of trough sorafenib concentration with overall survival (OS). Results The median sorafenib concentration was 2.91 μg/mL (range 0.74–8.8 μg/mL). Based on the receiver operating characteristic curve, the threshold value of the trough sorafenib concentration for predicting grade ≥ 3 toxicities and responder (complete response or partial response at best response, or stable disease for ≥ 3 months) was 3.45 μg/mL [area under the curve (AUC) 0.74, 95% confidence interval (CI) 0.54–0.93; p p <0.05), respectively. OS of patients with sorafenib 1.40–3.45 µg/mL had a tendency to be longer than those of patients administered < 1.40 μg/mL and ≥ 3.45 μg/mL [median 17.8 months (1.40–3.45 μg/mL) vs. 5.3 months (< 1.40 μg/mL) and 9.5 months (≥ 3.45 μg/mL)]. Conclusions From results of this study, we proposed that the target range of sorafenib may be a trough concentration of 1.40–3.45 μg/mL in patients with HCC.Keywords
This publication has 25 references indexed in Scilit:
- Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma—a meta-analysisEuropean Journal of Cancer, 2018
- Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?World Journal of Gastroenterology, 2018
- Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyondCancer Treatment Reviews, 2018
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studiesJournal of Hepatology, 2017
- Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III TrialsJournal of Clinical Oncology, 2017
- Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitorsPharmacology & Therapeutics, 2015
- Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell CarcinomaClinical Genitourinary Cancer, 2015
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006